{"id":31264,"date":"2025-04-07T14:30:33","date_gmt":"2025-04-07T06:30:33","guid":{"rendered":"https:\/\/flcube.com\/?p=31264"},"modified":"2025-04-07T14:30:34","modified_gmt":"2025-04-07T06:30:34","slug":"fujian-keruis-generic-sirolimus-gel-approved-by-chinas-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31264","title":{"rendered":"Fujian Kerui&#8217;s Generic Sirolimus Gel Approved by China&#8217;s NMPA"},"content":{"rendered":"\n<p>China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer&#8217;s (NYSE: PFE) Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.<\/p>\n\n\n\n<p><strong>Drug Profile<\/strong><br>The sirolimus gel, a topical mTOR inhibitor, has demonstrated quality and efficacy comparable to the originator product. It is the only available version of sirolimus gel in China, offering a new treatment option for patients with tuberous sclerosis.<\/p>\n\n\n\n<p><strong>Market Context<\/strong><br>Until now, Pfizer\u2019s Rapamune has been the sole option for patients requiring sirolimus gel therapy. The approval of Kerui\u2019s generic version is expected to increase accessibility and provide a more competitive pricing option in the market.<\/p>\n\n\n\n<p><strong>Investment Background<\/strong><br>In 2021, Shanghai-based medical device giant MicroPort Scientific Corp. (HKEX: 00853) acquired a 45% stake in Kerui Pharma for RMB 111 million (USD 15 million), becoming the company\u2019s largest shareholder. This investment underscores MicroPort\u2019s commitment to expanding its presence in the pharmaceutical sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer&#8217;s (NYSE: PFE)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31267,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,42,3940,863,309,15],"class_list":["post-31264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-first-mover-generic","tag-kerui-pharmaceutical","tag-nyse-pfe","tag-pfizer","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fujian Kerui&#039;s Generic Sirolimus Gel Approved by China&#039;s NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31264\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fujian Kerui&#039;s Generic Sirolimus Gel Approved by China&#039;s NMPA\" \/>\n<meta property=\"og:description\" content=\"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31264\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T06:30:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T06:30:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fujian Kerui&#8217;s Generic Sirolimus Gel Approved by China&#8217;s NMPA\",\"datePublished\":\"2025-04-07T06:30:33+00:00\",\"dateModified\":\"2025-04-07T06:30:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264\"},\"wordCount\":189,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0701-png.webp\",\"keywords\":[\"Cancer\",\"First-mover generic\",\"Kerui Pharmaceutical\",\"NYSE: PFE\",\"Pfizer\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31264#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31264\",\"name\":\"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0701-png.webp\",\"datePublished\":\"2025-04-07T06:30:33+00:00\",\"dateModified\":\"2025-04-07T06:30:34+00:00\",\"description\":\"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31264\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0701-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0701-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31264#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fujian Kerui&#8217;s Generic Sirolimus Gel Approved by China&#8217;s NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31264","og_locale":"en_US","og_type":"article","og_title":"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA","og_description":"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.","og_url":"https:\/\/flcube.com\/?p=31264","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-07T06:30:33+00:00","article_modified_time":"2025-04-07T06:30:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31264#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31264"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fujian Kerui&#8217;s Generic Sirolimus Gel Approved by China&#8217;s NMPA","datePublished":"2025-04-07T06:30:33+00:00","dateModified":"2025-04-07T06:30:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31264"},"wordCount":189,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31264#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","keywords":["Cancer","First-mover generic","Kerui Pharmaceutical","NYSE: PFE","Pfizer","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31264#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31264","url":"https:\/\/flcube.com\/?p=31264","name":"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31264#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31264#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","datePublished":"2025-04-07T06:30:33+00:00","dateModified":"2025-04-07T06:30:34+00:00","description":"China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer\u2019s Rapamune (sirolimus) has received marketing approval from the National Medical Products Administration (NMPA). This approval marks the first domestically produced sirolimus gel in China, indicated for the treatment of facial vascular fibroadenoma associated with tuberous sclerosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31264#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31264"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31264#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","width":1080,"height":608,"caption":"Fujian Kerui's Generic Sirolimus Gel Approved by China's NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31264#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fujian Kerui&#8217;s Generic Sirolimus Gel Approved by China&#8217;s NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0701-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31264"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31264\/revisions"}],"predecessor-version":[{"id":31268,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31264\/revisions\/31268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31267"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}